- Home
- IBRX vs VRDN Comparison
IBRX vs VRDN Comparison
Compare IBRX & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- VRDN
- Stock Information
- Founded
- IBRX 2014
- VRDN 2006
- Country
- IBRX United States
- VRDN United States
- Employees
- IBRX N/A
- VRDN N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- VRDN Medical Specialities
- Sector
- IBRX Health Care
- VRDN Health Care
- Exchange
- IBRX Nasdaq
- VRDN Nasdaq
- Market Cap
- IBRX 1.9B
- VRDN 1.6B
- IPO Year
- IBRX N/A
- VRDN N/A
- Fundamental
- Price
- IBRX $3.42
- VRDN $16.27
- Analyst Decision
- IBRX Strong Buy
- VRDN Buy
- Analyst Count
- IBRX 3
- VRDN 12
- Target Price
- IBRX $13.58
- VRDN $36.44
- AVG Volume (30 Days)
- IBRX 6.0M
- VRDN 979.5K
- Earning Date
- IBRX 03-18-2025
- VRDN 03-04-2025
- Dividend Yield
- IBRX N/A
- VRDN N/A
- EPS Growth
- IBRX N/A
- VRDN N/A
- EPS
- IBRX N/A
- VRDN N/A
- Revenue
- IBRX $7,332,000.00
- VRDN $302,000.00
- Revenue This Year
- IBRX $2,359.81
- VRDN $3.30
- Revenue Next Year
- IBRX $808.10
- VRDN N/A
- P/E Ratio
- IBRX N/A
- VRDN N/A
- Revenue Growth
- IBRX 1218.71
- VRDN N/A
- 52 Week Low
- IBRX $2.28
- VRDN $11.40
- 52 Week High
- IBRX $10.53
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- IBRX 52.26
- VRDN 36.43
- Support Level
- IBRX $3.35
- VRDN $15.62
- Resistance Level
- IBRX $4.27
- VRDN $18.15
- Average True Range (ATR)
- IBRX 0.31
- VRDN 0.91
- MACD
- IBRX 0.04
- VRDN -0.20
- Stochastic Oscillator
- IBRX 29.17
- VRDN 14.48
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.